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Abstract
Specialized glucosensing neurons are present in the hypothalamus, some of which neighbor the
median eminence, where the blood-brain barrier has been reported leaky. A leaky BBB implies
high tissue glucose levels and obviates a role for endothelial glucose transporters in the control of
hypothalamic glucose concentration, important in understanding the mechanisms of glucose
sensing We therefore addressed the question of blood-brain barrier integrity at the hypothalamus
for glucose transport by examining the brain tissue-to-plasma glucose ratio in the hypothalamus
relative to other brain regions. We also examined glycogenolysis in hypothalamus because its
occurrence is unlikely in the potential absence of a hypothalamus-blood interface. Across all
regions the concentration of glucose was comparable at a given plasma glucose concentration and
was a near linear function of plasma glucose. At steady-state, hypothalamic glucose concentration
was similar to the extracellular hypothalamic glucose concentration reported by others.
Hypothalamic glycogen fell at a rate of ∼1.5 μmol/g/h and remained present in substantial
amounts. We conclude for the hypothalamus, a putative primary site of brain glucose sensing that:
the rate-limiting step for glucose transport into brain cells is at the blood-hypothalamus interface,
and that glycogenolysis is consistent with a substantial blood -to- intracellular glucose
concentration gradient.
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Introduction
The brain is remarkable in its dependence on the blood for essentially two energy substrates,
i.e. glucose and oxygen. To maintain the brain's high rate of aerobic metabolism, transport
of glucose into the brain occurs through regionally selective, bidirectional, facilitated
transport (Lund-Andersen 1979; Pardridge 1983; Bradbury 1993). The brain
microenvironment is isolated from the plasma by the blood-brain barrier (BBB) formed by
tight junctions between vascular endothelial cells, where tightness excludes free diffusion of
polar, hydrophilic molecules such as glucose resulting in a constant and significant glucose
concentration gradient from blood to brain, i.e. approximately 5 to 1 ((Lund-Andersen 1979)
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and references therein; (Gruetter et al. 1998) and references therein; (Barros et al. 2007)).
Glucose is transported into brain by the major high affinity glucose transporter isoform
GLUT1 (Pardridge et al. 1990), distributed between the lumenal and ablumenal membranes
of the capillary endothelial cells that comprise the BBB in vivo (Carruthers 1990).
Increases of both GLUT1 synthesis and luminal GLUT1 mediate enhanced glucose transport
across the BBB into rat brain in hypoglycemia (Simpson et al. 2007). The integrity of the
BBB for glucose transport is therefore expected to profoundly impact the concentration of
glucose in the brain microenvironment ((Gruetter et al. 1998) and references therein) and in
brain cells that use glucose either as a signaling molecule or energy substrate for
phosphorylation and/or whose glucosensing is altered in hyper/hypoglycemia (Mobbs et al.
2001; Levin et al. 2004; Marty et al. 2005; Song and Routh 2005, 2006). This is particularly
relevant to the hypothalamus: two hypothalamic glucose-sensing structures, the arcuate
nucleus and the ventral medial nucleus neighbor the hypothalamic median eminence, a
circumventricular organ that lacks a strict BBB (Fry and Ferguson 2007). It has therefore
been suggested that the BBB at the hypothalamus is absent or leaky (Cheunsuang et al.
2006; Mountjoy and Rutter 2007). The potential absence of a diffusion barrier for glucose is
expected to lead to elevated hypothalamic glucose concentrations relative to that in other
brain regions. The question remains as to what the concentration of glucose in the
hypothalamus is since it is a key parameter linking glucose transport and metabolism
(Gruetter et al. 1998; Barros et al. 2007), and whether the brain tissue-to-plasma glucose
ratio in the hypothalamus is similar to other brain regions that have intact barriers.
When plasma glucose levels reach approximately 2 mM in hypoglycemia, decreases in
cerebral metabolic rates of glucose (CMRglc) have been reported to exceed those of oxygen
in the conscious rat (Ghajar et al. 1982) indicating that the brain uses other energy
substrates, one of which is glycogen. Brain glycogen, a predominantly glial store of glucose
equivalents, is an important endogenous energy source to maintain brain cell function when
blood-brain glucose transport becomes rate limiting during acute hypoglycemia (Choi et al.
2003; Gruetter 2003). Brain glycogen levels are sensitive to changes in tissue and plasma
glucose concentrations (Choi et al. 2003; Morgenthaler et al. 2006) and replete to levels
higher than pre-depletion levels in brain following a single episode of hypoglycemia (Choi
et al. 2003; Oz et al. 2003).
This rebound in glycogen, known to be neuroprotective through the breakdown into mostly
glucose-6-P which is glycolyzed to pyruvate and which has been suggested to support
neuronal metabolism in hypoglycemia, most likely in the form of lactate (Gruetter 2003),
may affect glucose sensing by specialized neurons as they also respond to lactate (Song and
Routh 2005), and this may in part explain loss of physiological counterregulatory defense
mechanisms in insulin-induced hypoglycemia in diabetic patients undergoing intensive
insulin therapy (Bolli 2003; Criego et al. 2005).
Strong evidence suggests that the hypothalamus is a key region in the brain responsible for
hypoglycemia sensing and for triggering physiological counterregulatory defense
mechanisms (Borg et al. 1997) and the question remains as to how glycogen metabolism is
affected in the putative primary site of glucose sensing, the hypothalamus. The potential
absence of a BBB at the hypothalamus is expected to lead to similar concentrations of blood
and brain glucose, i.e. glucose phosphorylation will only be limited when plasma glucose
approaches the Km of hexokinase (50μM), which is practically impossible and thus
glycogenolysis would be unlikely. The present work extends our pioneering NMR
spectroscopy data of the relationship between glucose concentration in blood and in the
brain by: (1) improving the spatial resolution of the measurements; and (2) by validating
Poitry-Yamate et al. Page 2
J Neurochem. Author manuscript; available in PMC 2009 May 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
previous NMR measurements of glucose and glycogen in brain tissue by a biochemical
method.
Therefore, the purpose of this study was: (1) to assess the integrity of the hypothalamic-
blood interface relative to other brain regions for the transport of glucose and (2) to examine
whether, in support of a functional hypothalamic-blood interface, the hypothalamus exhibits
glycogen breakdown. A preliminary report of part of this work has appeared (Poitry-Yamate
et al. 2007).
Material and Methods
Animal preparation
The study was performed in accordance with Swiss Federal guidelines for the care and use
of laboratory animals and was approved by the ethics committee. Male Sprague-Dawley rats
(Charles River, France) weighing between 250-280 grams were fasted overnight with access
to water. To enable comparison between biochemical and previous in vivo NMR studies,
measurements in the present study were obtained from hypoglycemic, euglycemic and
hyperglycemic rats following the same preparatory glycemic procedures carried out for in
vivo 1H and 13C NMR experiments (Choi et al. 2001). Briefly, 3 groups of animals were
studied at target plasma glucose levels: hypoglycemia (<2 mM), euglycemia (5-10 mM) and
hyperglycemia (>10 mM). All animals were initially anesthetized with 4% isoflurane in a
2:1 mixture of nitrous oxide and oxygen during induction. Isoflurane was lowered to 2%
during catheterization. Animals were artificially ventilated with a pressure-driven ventilator.
For hyperglycemia and hypoglycemia studies, α-chloralose was given as an 80mg/kg bolus
followed 10 min later by infusion at a rate of 27mg/kg/h. Hyperglycemic animals were
maintained at a level of ∼17mM plasma glucose by adjustment of glucose infusion rate.
Insulin (1U/ml Humulin®; Lilly Inc, Paris, France) was administered to reach a target
hypoglycemia condition of plasma glucose < 2mM for 2-3 hours. The duration of
hypoglycemia and hyperglycemia before blood sampling and brain fixation was on average
3 and 7 hours, respectively. Because no significant difference was found for total brain
glucose and glycogen as a function of plasma glucose between the light anesthetics
isoflurane and α-chloralose (Morgenthaler et al., 2006), we elected to use only isoflurane
anesthesia in the euglycemic studies. Plasma glucose in euglycemic animals was maintained
between 5-10mM by adjustment of glucose infusion rate.
Microwave fixation and brain dissection
After final blood sampling, anesthetized animals underwent focused microwave irradiation
of 4kW at 2450 MHz for 2s (Gerling Applied Engineering Inc., CA, USA). 2s was sufficient
to provide absorption of microwave energy (and hence heat generation and subsequent
temperature rise) between superficial and deep brain regions. Decapitation was performed
after microwave fixation. We have established that this approach leads to minimal agonal
metabolism as verified from the tissue lactate levels (Morgenthaler et al. 2006). The cortical
surface of the brain was then exposed, meninges removed and 5 brain regions of interest
were dissected within 2 minutes in the following order: olfactory bulb, hypothalamus, then
coronal sections of frontal cortex, hippocampus and cerebellum. Care was taken to
consistently take the same region in coronal sections and to keep tissue sample volumes
similar, i.e. < 1×3×3mm3 or ∼ between 5-10 mg of wet weight tissue.
Biochemical measurements
Following the determination of wet weight of each freshly dissected brain sample, the
sample was immediately immersed in 250 μl of 0.03 M HCl, the contents were homogenized
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using an ultrasonic homogenizer probe microtip (Bandelin, Berlin, Germany), and
immediately divided into two equal volumes, one for determination of free glucose and the
second for the determination of digested glycogen plus free glucose.
The release of glucose from glycogen by amyloglucosidase (10mg/ml, Roche Applied
Science, Rotkreuz, Switzerland) was performed following the procedure described by Cruz
and Dienel (Cruz and Dienel 2002). Samples digested by amyloglucosidase from tissue at
euglycemia and hyperglycemia were diluted between 2- to 5-fold in water (pH 7.4) such that
spectroscopic absorbance values fell in the middle of the glucose-absorbance calibration
curve (see below). Tissue glucose, whether for the background or digested sample, was
assayed using Trinder's method (Amplex Red, Invitrogen, Basel, Switzerland) and the
samples in the present study were not frozen prior to glucose measurements. Glucose
Standards, prepared from commercially available D-glucose, were left at room temperature
for ∼3h prior to use. This assay is based on glucose oxidase digestion, forming H2O2 which
reacts with peroxidase substrate in the presence of horseradish peroxidase to generate
resorufin. All samples, including standards, were brought to pH 7,4 using NaOH and equal
volumes of samples and reaction buffer reagent, typically 60 μl, were used. 100μl of the
final 120μl solution of (sample + reaction buffer reagent) was transferred under dim room
light to a 96 well microplate and left in darkness for 30 minutes at room temperature before
absorption measurements. Maximum absorbance was attained at room temperature at
λ=560nm, pH>7, 30 min after the reagent was added. Absorbance as a function of D-glucose
concentration was measured using a Biotek Powerwave XS spectrophotometer (Bio-Tek
Instruments, Inc. Vermont, USA).
Absorbance values of brain glucose and brain glycogen, i.e. the difference between digested
and background glucose) were expressed in units of μmol/g wet weight using the equation:
(Eq 1)
where Vab is the absorbance value, A is the y-intercept; and B the slope from linear
regression plots of absorbance as a function of glucose concentration. H is the starting
dilution factor = (mg tissue wet weight) / (250 μl 0.03M HCl + mg tissue wet weight).
Determination of glucose transport kinetics
To allow comparison with previous whole-brain rat NMR results, i.e. under similar
experimental conditions and anesthesia protocols, we measured brain glucose as a function
of plasma glucose at steady-state and express the relationship as a linear function and report
the apparent kinetic constants (Gruetter et al. 1998; Pfeuffer et al. 2000; Choi et al. 2001;
Lei and Gruetter 2006) from the linear regression plots of plasma glucose and tissue glucose
using the expression:
(Eq 2)
Where G is the concentration of glucose by brain region indicated (μmol/g) or in plasma
(mmol/L); Vd = 0.77 mL/g, the physical distribution space of water in brain; Tmax is the
apparent maximum transport rate, CMRglc is the cerebral metabolic rate of glucose
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utilization and Kt, the apparent Michaelis-Menten constant. The equation was fitted using
OriginPro 7.5
Results
To measure glucose and/or glycogen from small volumes (5-10 μL) of tissue samples, we
implemented an enzymatic-absorbance based assay previously used in quantifying hepatic
glycogen (Dong et al. 2006) and plasma glucose (Koch and Nipper 1977). This assay was
inherently sensitive, and between 0.00095 to ∼ 0.125 mM glucose, with a precision of < 2%
(Fig 1). Omission of the Amplex Red reagent (shown by the dotted line) to verify reaction
specificity resulted in constant absorbance.
Tissue glucose concentrations were comparable at a given plasma glucose concentration
across all brain regions, averaging 1.6 μmol/g at euglycemia (5-10 mM plasma glucose), 0.2
μmol/g at hypoglycemia (<2mM plasma glucose) and 4.0 μmol/g at hyperglycemia (10-22
mM plasma glucose). In all 5 brain regions the concentration of tissue glucose consistently
increased in a nearly linear fashion with plasma glucose concentration (Fig 2). Of particular
interest was the 5:1 ratio observed at euglycemia between glucose concentration in blood
and hypothalamus (Fig 2). The brain/plasma glucose concentration ratio indicated for each
brain region in Fig 2 was similar in the various brain structures and not statistically
significant from each other.
The relationship between brain and plasma glucose concentration was fit using Equation 2.
Values of Tmax/CMRglc varied from 2.5 ± 0.2 (hypothalamus and cortex), 1.9 ± 0.2
(cerebellum). Kt was on the order of a few mM: 3.2 ± 0.9 mM in hippocampus and cortex;
1.5 ± 0.9 mM in olfactory bulb, 0.1 ± 1.0 mM in cerebellum and 2.6 ± 1.1mM in
hypothalamus.
The effect of glycemia on glycogen concentration and metabolism in the hypothalamus is
shown in Table 1 and compared to 4 other brain regions. After 2 hours of hypoglycemia (<
2mM plasma) glycogen remained present in substantial amounts in all 5 brain regions.
Glycogen was reduced from ∼4.5 to ∼1.6 μmol/g, equivalent to a rate of ∼ 0.025 μmol/g/
min (for hypothalamus, cortex and cerebellum) and from ∼3.2 to ∼1.8, equivalent to a rate
of ∼0.011 μmol/g/min (for olfactory bulb and hippocampus). When plasma glucose was
raised to >10 mM from euglycemia, glycogen content increased slightly in all 5 regions and
reached statistical significance in olfactory bulb (p < 0.001, Table 1).
Levels of tissue glycogen and glucose as a function of plasma glucose for the hypothalamus
and cortex are given in Table 1 and Fig 2, and show that in both regions glycogen exceeds
glucose levels.
Discussion
We implemented a highly sensitive and reproducible enzyme and absorbance-based assay
using glucose oxidase (Fig 1). In conjunction with uniform microwave fixation of superficial
and deep brain regions, the enzymatic assay allowed the use of small, 10μl volumes of tissue
with minimal partial volume effects. It is important to note that beyond 125 μM glucose, the
absorption of resorufin was no longer linear (Fig 1, inset), necessitating care to choose
appropriate sample dilutions. We went on to use this biochemical assay to determine
whether the brain tissue-to-plasma glucose ratio was similar in the hypothalamus compared
to other brain regions of α-chloralose anesthetized rats, and also at hypoglycemia and
hyperglycemia.
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The linearity shown in Fig 2 by brain region was in excellent agreement with that previously
measured for whole brain and lends support to the notion that the whole brain represents the
weighted average of the levels of its component parts (Gruetter et al. 1996;Gruetter et al.
1998;Choi et al. 2001;de Graaf et al. 2001;Choi et al. 2002;Lei and Gruetter 2006).
The similar brain tissue-to-plasma glucose ratio between hypothalamus and the other
anatomically distinct brain regions (Fig 2) suggests similar glucose transport kinetics.
Implicit in all aforementioned glucose transport models is the assumption that: (1) the
concentration gradient of glucose is primarily at the entry of glucose into the brain, i.e. the
endothelial cells or astrocytic endfoot processes, and (2) that glucose is uniformly
distributed in the brain aqueous phase beyond the BBB. Indeed, a ∼5:1 ratio of plasma to
tissue glucose concentration at euglycemia across all brain regions, including the
hypothalamus (Fig 2) supports the presence of a significant glucose concentration gradient
from blood to brain (Gruetter et al. 1992;Gruetter et al. 1996;Gruetter et al. 1998). Total
tissue glucose concentrations, which represent extracellular and intracellular glucose levels,
have been indirectly assessed from the equilibrium brain/plasma distribution ratio of 3-0-
methyl-D-glucose (Gjedde and Diemer 1983;Namba et al. 1987;Dienel et al.
1991;Nakanishi et al. 1996) implying a relative regional uniformity of brain glucose
concentrations. However, 3-0-methyglucose differences between the extracellular space and
intracellular space have not been established.
We have previously shown that deep anesthesia increases brain glucose content at a given
plasma glucose concentration (Choi et al. 2002) and the anesthesia in the present study
might have led to an overestimated hypothalamic glucose concentration. However, the
presence of a significant blood/brain glucose concentration gradient in anesthetized brain
only underlines the presence of a significant diffusion barrier for glucose entry into the
hypothalamus.
When comparing the tissue glucose measurements with extracellular, i.e. interstitial glucose
measurements in hypothalamus (Fig 3) the two were on the same order of magnitude and
clearly lower than the plasma glucose concentration, with the implication that at steady-
state, glucose concentrations are similar in the intracellular and extracellular space. This
observation strongly suggests a structural and functional transport barrier for glucose entry
across the hypothalamus-blood interface. Even if deeper anesthesia was used in some of the
extracellular measurements used for Fig 4, the main conclusion is unaffected by the specific
degree of anesthesia, since deeper anesthesia tends to reduce the concentration gradient
(Choi et al. 2002).
In addition to the BBB, other potential routes of entry of glucose into the hypothalamus are
indirectly via the cerebrospinal fluid (CSF) (Broadwell et al. 1983) or via transport-
independent mechanisms (Faouzi et al. 2007). A significant CSF-to-median eminence
exchange that would elevate the concentration of glucose preferentially in hypothalamus is,
however, unlikely: immunohistochemical evidence shows low to absent expression of
GLUT1 in hypothalamic β2-tanycytes that participate in forming an efficient barrier system
between the median eminence and CSF (Peruzzo et al. 2000; Garcia et al. 2001) and influx
is expected to be minimal due to a 103-fold lower circumventricular organ surface area
relative to that of the BBB (Kastin and Pan 2006).
The relationship established between increased whole brain glucose concentration and
reported changes of endothelial GLUT1 protein in sustained hypoglycemia suggests that a
normal glucose environment in brain can be created as a consequence of increased GLUT1
expression and up-regulation and/or sequestration of GLUT1 protein at the BBB mediated
by ambient glucose concentration (Lei and Gruetter 2006). Such a mechanism is a likely
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alternative explanation to the observed hypoglycemia unawareness in patients undergoing
intensive insulin treatment of diabetes, although sequestration of GLUT1 at the BBB might
also allow for acute regulation of glucose transport (Barros et al. 2005). The similar values
obtained of kinetic constants for glucose transport at steady-state between whole brain
measurements and anatomically and functionally distinct brain regions suggests that such a
blunting of normal glucose sensing by the brain may specifically involve increased GLUT1
expression and up-regulation and/or sequestration of GLUT1 protein at the BBB at the
hypothalamus, a key glucose sensing region for triggering hypoglycemic counterregulatory
defense mechanisms (Borg et al. 1997).
Under euglycemic conditions, the concentration of glycogen in all 5 regions of the brain was
higher than that of the corresponding brain glucose (compare Fig 2 and Table 1) suggesting
that the brain synthesizes and stores glycogen as a likely reserve supply of energy (Gruetter
2003). Indeed, the finding that 2 hours of severe, acute hypoglycemia did not completely
deplete brain glycogen in any brain region studied (Table 1) demonstrates that functionally
distinct areas of the brain may survive extended periods of hypoglycemia through
glycogenolysis. These observations extend the importance of glycogen as being
neuroprotective when BBB glucose transport becomes rate-limiting for glucose metabolism
(Choi et al. 2003;Lei and Gruetter 2006;Morgenthaler et al. 2006;Suh et al. 2007). At a
plasma glucose concentration of 1.5 mM attained during hypoglycemia in the present study,
we estimated a 10% glucose deficit in hypothalamus, cortex and hippocampus. Therefore,
glycogenolysis accounts for a substantial fraction of the estimated 10% glucose supply
deficit for all reported and estimated glucose metabolic rates (Sokoloff et al. 1977), as
previously reported for whole rat brain (Choi et al. 2003).
Similar net glycogen utilization rates in cortex and hippocampus have been reported in
unrestrained rats (Herzog et al. 2008), after taking into account differences in the severity
and duration of hypoglycemia (1.9 vs 1.5mM; and 3 vs 2 hour). However, in that study the
reported glycogenolytic rate was 50% lower than ours in the hypothalamus and this
difference cannot be explained by differences in the measured, control glycogen
concentrations, which were similar.
In previous brain studies, hyperglycemia was shown to increase glycogen content (Nelson et
al. 1968; Swanson et al. 1989; Morgenthaler et al. 2006). Here, a similar trend was observed
(Table 1) but not statistically significant for all brain regions. Future studies are needed to
establish glycogen levels and brain tissue-to-plasma glucose ratios by brain region in
hyperglycemia, which would suggest that tissue glucose itself may affect glycogen levels.
In conclusion, biochemical evidence has been presented in support of a functional
hypothalamus-blood interface for the transport of glucose. We speculate that in such an
environment, specialized glucosensing neurons in the hypothalamus may effectively monitor
and respond to the availability of glucose (for reviews, see (Routh et al. 2004; Marty et al.
2007; McCrimmon 2008)). In this connection, and beyond the BBB, accumulating evidence
shows that neuron function is finely modulated by surrounding glia, such that these 2 major
cell types interact synergistically (Poitry-Yamate et al. 1995), inviting the question as to the
extent the process of glucose sensing is altered by the function of glial cells and glial
glycogen.
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Fig 1.
Sensitivity, linearity and reproducibility of glucose assay using glucose oxidase. Standards
of D-glucose ranging from 0.00095 to ∼0.125 mM were linearly related to absorbance of
resorufin at 560 nanometers in the presence of reagent (n = 6 replicates). The dotted line
corresponds to the fit of the same glucose standards in the absence of reagent (n = 2
replicates). Inset shows regions of non-linearity of assay, starting from arrow.
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Fig 2.
Relationship between brain and plasma glucose concentration from anatomically and
functionally distinct brain regions. Regression lines of plots show the best-fit of the model of
glucose transport (as described in Material and Methods) to the data points measured
biochemically over an extended range of plasma glucose levels (∼ 1.4 to 22 mM). All brain
regions showed near linearity. The mean values of the slope ± SD by brain region are
indicated. Linear regression plots were then used to determine the kinetic parameters, Kt and
Tmax/CMRglc (see text). > 40 independent glucose measurements were performed per brain
region except for cerebellum (N = 19).
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Fig 3.
Comparison of tissue and interstitial glucose concentration for hypothalamus as a function
of plasma glucose. The concentrations of hypothalamic glucose (open squares) were those
determined in the present study (Fig 2) at plasma glucose concentrations (in mM) of 1.5 ±
0.03; 7.9 ± 0.1; 9.8 ± 0.1; n=5 per point. Interstitial glucose concentrations: zero-net flux in
unrestrained rats (closed squares) from (de Vries et al. 2003); and implanted glucose
microelectrodes in pentobarbital-anesthetized rats (closed triangles) from (Silver and
Erecinska 1994). R2 refers to hypothalamic tissue glucose.
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Table 1
Glycogen content by brain region and plasma glucose concentration. Values are mean μmol/g ± SD based on
(n measurements). Glycogen content in hypoglycemia and hyperglycemia was compared to that in euglycemia
using two-way ANOVA following the Bonferroni post-tests. * indicates a significant difference for P<0.05; **
for P<0.01 and *** for P<0.001.
Hypoglycemia
<2 mM
Euglycemia
5-8 mM
Hyperglycemia
>10 mM
hypothalamus 1.9±0.8 (8)*** 4.4±1.0 (14) 5.5±1.6 (7)
cortex 0.9±1.2 (5)** 4.0±1.4 (13) 5.1±1.9 (9)
olfactory bulb 1.7±1.0 (8) 2.9±0.8 (16) 5.1±1.4 (8) ***
hippocampus 1.8±1.5 (7) 3.4±1.1 (13) 3.4±1.9 (8)
cerebellum 1.5±1.3 (5)** 4.4±1.6 (5) 6.1±1.9(4)
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